Which manufacturer is the original drug of Platinib?

Pralsetinib is a targeted drug used to treat certain types of non-small cell lung cancer (NSCLC), especially cancers with RET gene mutations. The drug was developed by Blueprint Medicines, a biopharmaceutical company in the United States. Blueprint Medicines is committed to developing innovative drugs for the targeted treatment of major diseases such as cancer. Platinib is one of the company's key drugs being developed to treat cancers associated with RET mutations. By inhibiting the proliferation of cancer cells caused by RET gene mutations, platinib can effectively prevent the growth of cancer cells and delay tumor progression.

The commercialization partner of the drug is Swiss pharmaceutical giant Roche (Roche). In 2020, platinib was approved for the treatment of RET non-small cell lung cancer with positive gene mutations, marking the global launch of this drug. Roche is responsible for the sales and distribution of platinib in most regions around the world, ensuring that the drug can enter the market quickly and provide treatment opportunities for more patients.

However,2023In 2023, Blueprint Medicines announced that it had regained the global commercialization and research and development rights of platinib. This move enables Blueprint Medicines to regain control of the global market for platinib and strengthen its strategic layout in the field of cancer treatment. At this time, Roche still retains sales rights to Greater China. Therefore, Platinib’s commercialization partner in Mainland China, Hong Kong, Macau and Taiwan is CStone Pharmaceuticals (CStone Pharmaceuticals), which is responsible for the development and sales of Platinib in China.

Generally speaking, the research and development and production of platinib are led by Blueprint Medicines, while its global distribution and sales are carried out through cooperation with Roche and CSPC. With the continuous progress in the treatment field, platinib is expected to be widely used in patients in more countries and regions, becoming one of the important drugs for the treatment of RET mutation-related cancers.

Reference materials:https://gavreto.com/